Faslodex (fulvestrant), a new drug for metastatic breast cancer

June 2002

You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.

It's for postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.

In these women, Faslodex delays tumor progression at least as well as the aromatase inhibitor Arimidex (anastrozole).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new guidelines for treating sexually transmitted diseases (STDs)
Osteoporosis Actonel (risedronate) will soon come in a new 35 mg tablet for once-a-week dosing
Gastroenterology Some OTC laxatives will be taken off the market or reformulated
Contraceptives two new alternatives to oral contraceptives
inhaled beta-agonists MIGHT increase the risk of MI in COPD patients
coenzyme Q10 to PREVENT migraines
New guidelines will help clarify how to treat bipolar disorder
Cardiology Benicar (olmesartan), a new angiotensin receptor blocker for hypertension
new home diagnostic test kits
Hematology & Oncology the use of soy in women with breast cancer
Hematology & Oncology Faslodex (fulvestrant), a new drug for metastatic breast cancer
Women's Health many women are asking how to discontinue HRT
Women's Health Zoloft (sertraline) for premenstrual dysphoric disorder (PMDD)
Diabetes recent media reports that "metformin is dangerous"
Gastroenterology the approval of restricted use of Lotronex